Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by M.D. Sass LLC

M.D. Sass LLC grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 391,824 shares of the medical research company’s stock after purchasing an additional 70,652 shares during the quarter. Charles River Laboratories International comprises about 5.4% of M.D. Sass LLC’s portfolio, making the stock its 2nd biggest position. M.D. Sass LLC owned approximately 0.77% of Charles River Laboratories International worth $72,331,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CRL. Virtu Financial LLC acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at about $601,000. JPMorgan Chase & Co. grew its stake in Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after acquiring an additional 85,759 shares during the period. State Street Corp grew its stake in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Charles River Laboratories International by 7.6% during the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after acquiring an additional 3,268 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International during the third quarter worth approximately $966,000. Institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $167.29 on Tuesday. The company has a market capitalization of $8.55 billion, a P/E ratio of 1,115.28, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company’s 50-day moving average is $165.66 and its 200 day moving average is $183.49. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $273.57.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the previous year, the company earned $2.46 earnings per share. The company’s quarterly revenue was down 1.1% on a year-over-year basis. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $190.00 to $170.00 in a research report on Friday. UBS Group reaffirmed a “neutral” rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Bank of America decreased their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, Barclays dropped their target price on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $189.77.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).